Jazz Pharmaceuticals plc — Director's Dealing 2015

Dec 3, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2015-12-01

Reporting Person: ENRIGHT PATRICK G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-12-01	Ordinary Shares	S	4672	$145.9632	Disposed	240416	Indirect
2015-12-01	Ordinary Shares	S	3395	$146.9515	Disposed	237021	Indirect
2015-12-01	Ordinary Shares	S	1737	$147.5758	Disposed	235284	Indirect
2015-12-01	Ordinary Shares	S	94	$145.962	Disposed	4818	Indirect
2015-12-01	Ordinary Shares	S	68	$146.9547	Disposed	4750	Indirect
2015-12-01	Ordinary Shares	S	34	$147.5742	Disposed	4716	Indirect
2015-12-02	Ordinary Shares	S	424	$148.49	Disposed	1310	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.39 to $146.3837. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: The Reporting Person is a managing member of Longitude Capital Partners, LLC, the general partner of each of Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. The Reporting Person disclaims beneficial ownership of the securities of the Issuer held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. except to the extent of his pecuniary interest therein.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $146.39 to $147.37. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.42 to $147.93. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.39 to $146.3837. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $146.39 to $147.37. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.42 to $147.93. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.